Greenwich LifeSciences, Inc.
GLSI
$9.48
-$0.385-3.91%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 340.87% | 23.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 196.22% | 2.54% | |||
| Operating Income | -196.22% | -2.54% | |||
| Income Before Tax | -201.28% | -2.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -201.28% | -2.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -201.28% | -2.38% | |||
| EBIT | -196.22% | -2.54% | |||
| EBITDA | -196.30% | -2.54% | |||
| EPS Basic | -201.08% | -0.54% | |||
| Normalized Basic EPS | -201.18% | -0.55% | |||
| EPS Diluted | -201.08% | -0.54% | |||
| Normalized Diluted EPS | -201.18% | -0.55% | |||
| Average Basic Shares Outstanding | 0.04% | 1.83% | |||
| Average Diluted Shares Outstanding | 0.04% | 1.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||